• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9.

作者信息

Lee So-Ryoung, Park Byoung-Won, Kim Jae Heon

机构信息

Department of Cardiology, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, South Korea.

Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University Medical College, Seoul, South Korea.

出版信息

Eur Urol. 2019 Mar;75(3):e57-e58. doi: 10.1016/j.eururo.2018.10.002. Epub 2018 Oct 14.

DOI:10.1016/j.eururo.2018.10.002
PMID:30327271
Abstract
摘要

相似文献

1
Re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9.回复：克里斯蒂安·格拉茨克、罗布·范·马南、克里斯托弗·查普尔等。米拉贝隆与索利那新联合治疗与单药治疗膀胱过度活动症患者的长期安全性和疗效比较：一项随机、多中心3期研究（SYNERGY II）。《欧洲泌尿外科杂志》2018年；74卷：501 - 509页。
Eur Urol. 2019 Mar;75(3):e57-e58. doi: 10.1016/j.eururo.2018.10.002. Epub 2018 Oct 14.
2
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9.对李素英、朴炳元及金在勋致编辑信的回复，信中提及克里斯蒂安·格拉茨克、罗布·范·马南、克里斯托弗·查普尔等人的文章：米拉贝隆与索利那新联合用药对比单药治疗膀胱过度活动症患者的长期安全性和有效性：一项随机、多中心3期研究（SYNERGY II）。《欧洲泌尿外科杂志》2018年；74卷：501 - 509页
Eur Urol. 2019 Mar;75(3):e59-e60. doi: 10.1016/j.eururo.2018.10.001. Epub 2018 Oct 26.
3
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE).回复：米拉贝隆联合索利那新治疗对初始4周索利那新单药治疗反应不佳的尿失禁型膀胱过度活动症患者的疗效和安全性：一项随机双盲多中心3B期研究（BESIDE）
J Urol. 2017 Mar;197(3 Pt 1):767-768. doi: 10.1016/j.juro.2016.12.081. Epub 2016 Dec 18.
4
Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).米拉贝隆与索利那新联合治疗膀胱过度活动症患者的疗效和安全性：一项随机、双盲、剂量范围、2 期研究（Symphony）的结果。
Eur Urol. 2015 Mar;67(3):577-88. doi: 10.1016/j.eururo.2014.02.012. Epub 2014 Feb 19.
5
Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).回复：米拉贝隆联合索利那新治疗对初始4周索利那新单药治疗反应不佳的尿失禁型膀胱过度活动症患者的疗效和安全性：一项随机双盲多中心3B期研究（BESIDE）
Eur Urol. 2016 Nov;70(5):892. doi: 10.1016/j.eururo.2016.08.027. Epub 2016 Aug 25.
6
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).米拉贝隆附加治疗对初始 4 周索利那新单药治疗反应不足的失禁型逼尿过度活动症患者的疗效和安全性：一项随机双盲多中心 3B 期研究（BESIDE）。
Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8.
7
Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).米拉贝隆与索利那新联合用药对比单药治疗及安慰剂治疗对膀胱过度活动症患者的疗效和安全性（协同研究）
BJU Int. 2017 Oct;120(4):562-575. doi: 10.1111/bju.13882. Epub 2017 Jun 8.
8
Re: Efficacy and Safety of Combinations of Mirabegron and Solifenacin Compared with Monotherapy and Placebo in Patients with Overactive Bladder (SYNERGY Study).关于：米拉贝隆与索利那新联合用药与单药治疗及安慰剂相比在膀胱过度活动症患者中的疗效和安全性（协同研究）
J Urol. 2018 Sep;200(3):502-505. doi: 10.1016/j.juro.2018.05.139. Epub 2018 Jun 5.
9
RE: Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.关于：米拉贝隆与索利那新单药治疗膀胱过度活动症的疗效和安全性的荟萃分析
Neurourol Urodyn. 2019 Aug;38(6):1792. doi: 10.1002/nau.24049. Epub 2019 Jun 3.
10
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).米拉贝隆作为索利那新治疗膀胱过度活动症患者的“附加”疗法的安全性和有效性：日本的一项上市后开放标签研究（MILAI研究）。
BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23.